Skip to main content

Fiscal Wizard · Single-issue tearsheet

CVKD / Jun 21, 2026 Run #7507

CVKD

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Composite verdict

F 11.8 / 100
Bearish setup · Crossover 11 drivers · 7 gates blocking
  • ADX DI Cross
  • Fibonacci Retracement
  • Rate of Change
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 417th of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: downtrend
Bull 0%Evidence: High · 19 signals100% Bear
Momentum Bearish 1Mean-reversion Neutral 50

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes from

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

23.6 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EPS Growth (YoY) 96
Return on Capital Employed 0
P/B 75
Return on Assets 0
Greenblatt ROC 0

Technicals Bearish

0.0 / 100

Bearish setup leads (ADX DI Cross, Fibonacci Retracement, Rate of Change); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
ADX DI Cross 11
Rate of Change 17
Fibonacci Retracement 17

Risk Gates

7 blocking 2 caution

7 guards active, 20 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for CVKD.